Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the...
We’re Bearish, but we’re up 243% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs